Genetic Evaluation of IL12B and ITGB7 Therapeutic Pathways in Inflammatory Bowel Disease: Implications for Childhood Bone Health
Authors:
- Maher AlhatlaniMAMaher Alhatlani
- Fatin AldenainiFAFatin Aldenaini
- Zinab A. SawanZSZinab A. Sawan
- Fay AldenainiFAFay Aldenaini
- Rafa M. AlHujailiRARafa M. AlHujaili
- Syeda Nilofer JahanSJSyeda Nilofer Jahan
- Sarah AldosariSASarah Aldosari
- Salem AlmasrahiSASalem Almasrahi
- Waleed A. AlkulaibiWAWaleed A. Alkulaibi
- Mohammed Shahab UddinMUMohammed Shahab Uddin
Preprint
- 5 November 2026
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Genetic evaluation of therapeutic targets can clarify disease-pathway relevance and developmental compatibility in inflammatory bowel disease (IBD). We performed two-sample drug-target Mendelian randomization using cis-pQTL instruments for IL12B and ITGB7, evaluating IBD, Crohn disease, ulcerative colitis, and childhood total-body bone mineral density (BMD), with pediatric total-body-less-head BMD replication. Four IL12B and two ITGB7 instruments were retained. Higher genetically proxied IL12B abundance was associated with IBD (OR, 1.341; 95% CI, 1.280–1.405), Crohn disease (OR, 1.357; 95% CI, 1.278–1.441), and ulcerative colitis (OR, 1.339; 95% CI, 1.262–1.420), whereas ITGB7 showed no convincing disease association. Neither target showed convincing evidence of a major effect on childhood BMD; replication was inconclusive, with lower precision for ITGB7. Primary colocalization showed no supportive evidence of a shared causal signal; IL12B–IBD strongly favored distinct signals (H3 = 0.999995; H4 = 5.07 × 10⁻⁶). Exploratory fine-mapping suggested possible sharing with a secondary IBD component, but this finding was prior-sensitive and limited by LD-reference reliability. Bayesian analyses were compatible with small IL12B BMD effects, whereas ITGB7 remained less precise. Overall, these findings support IL12B-related pathway relevance while informing developmental compatibility rather than drug efficacy or clinical safety.Keywords
All Related Versions
This publication has 58 references indexed in Scilit:
- Prevalence and predictors of low bone mineral density in pediatric inflammatory bowel diseaseJournal of Pediatric Gastroenterology and Nutrition, 2025
- Bone health screening practices with dual‐energy X‐ray absorptiometry and prediction of abnormal results in pediatric inflammatory bowel diseaseJournal of Pediatric Gastroenterology and Nutrition, 2023
- Effectiveness and Safety of Ustekinumab for Pediatric Inflammatory Bowel Disease: A Systematic ReviewPediatric Drugs, 2023
- Therapeutic targets for inflammatory bowel disease: proteome-wide Mendelian randomization and colocalization analysesEBioMedicine, 2023
- Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn’s Disease: The IM-UNITI TrialClinical Gastroenterology and Hepatology, 2022
- Growth Delay in Inflammatory Bowel Diseases: Significance, Causes, and ManagementDigestive Diseases and Sciences, 2021
- Pediatric-onset inflammatory bowel disease poses risk for low bone mineral density at early adulthoodDigestive and Liver Disease, 2017
- Risk of diagnosed fractures in children with inflammatory bowel diseasesInflammatory Bowel Diseases, 2011
- Gender differences in body composition deficits at diagnosis in children and adolescents with Crohnʼs diseaseInflammatory Bowel Diseases, 2007
- Natural history of bone metabolism and bone mineral density in children with inflammatory bowel diseaseInflammatory Bowel Diseases, 2007